Drug
Tedizolid phosphate clinical trials
Also written TR-701 FA, MK-1986 and Sivextro.
A product of Tedizolid; its studies count on that page too.
Keep track of what changes. Save the tedizolid phosphate studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Other names
Combined with it in one product
Studies by the year they started
30 studies that test it; most in 2012 (5)
| Year | Studies |
|---|---|
| 2008 | 4 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 5 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 27 · Other 3
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (18) · Merck Sharp & Dohme LLC (5) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · Tourcoing Hospital (1) · Dong-A ST Co., Ltd. (1) · Bayer (1) · Amit.Pai (1) · Assistance Publique - Hôpitaux de Paris (1)
Often tested with
Tested in the same studies.
Tyramine (1) · Midazolam (1) · Rosuvastatin (1) · Linezolid (1)
Studies
Open first, then newest update. How each study uses tedizolid phosphate is read from its arms, and is right about nine times in ten.
Testing it · 30
- Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)RecruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT05534750Written as Tedizolid arm (SIVEXTRO®)
- A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)CompletedPhase 3Merck Sharp & Dohme LLCNCT03176134Written as Tedizolid phosphate
- A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)CompletedPhase 1Merck Sharp & Dohme LLCNCT03217565Written as IV Tedizolid Phosphate
- A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043)CompletedPhase 1Merck Sharp & Dohme LLCNCT06733688Written as Tedizolid Phosphate Oral Formulation 1 (Reference)
- Tedizolid Prolonged Treatment for Prosthetic Joint InfectionsCompletedNot applicableTourcoing HospitalNCT03378427Written as Tedizolid Phosphate 200 MG [Sivextro]
- Phase I Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of DA-7218 in Healthy Male VolunteersCompletedPhase 1Dong-A ST Co., Ltd.NCT02097043Written as DA-7218
- A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)CompletedPhase 1Merck Sharp & Dohme LLCNCT02750761Written as Tedizolid Phosphate (IV)
- Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure InfectionsCompletedPhase 2Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00761215Written as TR-701 200 mg
- Microdialysis and Pharmacokinetic Study of TR-701CompletedPhase 1Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00666601Written as TR-701 (pro-drug)
- Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mgCompletedPhase 1Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01271998Written as TR-701 FA
- Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)CompletedPhase 3Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT02276482Written as Tedizolid Phophate
- Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002)CompletedPhase 3Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT02019420Written as Tedizolid phosphate
- Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent PatientsCompletedPhase 1Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01156077Written as TR-701 FA
- A Thorough QT Study of TR-701free Acid (FA) in Healthy SubjectsCompletedPhase 1Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01461460Written as TR-701 FA 1200 mg
- Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) InfectionsCompletedPhase 3BayerNCT01967225Written as Tedizolid Phosphate (Sivextro, BAY1192631)
- TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsCompletedPhase 3Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01421511Written as TR-701 FA
- A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA StudyCompletedPhase 2Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01519778Written as TR701 FA
- TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.CompletedPhase 3Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01170221Written as TR-701 FA
- A Phase 1 Crossover Study of Blood Pressure and Heart Rate ResponseCompletedPhase 1Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01577459Written as TR-701 FA with PSE
- Food Effects of Single Oral Dose of 600mg TR-701CompletedPhase 1Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00671359Written as TR-701 600mg
Codes
What other systems call tedizolid phosphate · ClinicalTrials.gg INT004993
- MeSH (NLM) C515040tedizolid phosphateConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) O7DRJ6R4DWTEDIZOLID PHOSPHATEConfirmed FDA, NLM, Wikidata
- RxNorm 1540824Confirmed FDA, Wikidata
- Wikidata Q21011227tedizolid phosphateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152537Tedizolid PhosphateOne source FDA
- DrugBank DB09042One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C515040 | tedizolid phosphate | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | O7DRJ6R4DW | TEDIZOLID PHOSPHATE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1540824 | — | Confirmed FDA, Wikidata |
| Wikidata | Q21011227 | tedizolid phosphate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152537 | Tedizolid Phosphate | One source FDA |
| DrugBank | DB09042 | — | One source Wikidata |
Also registered as torezolid phosphate disodium (UNII 0SVV6ZD7JQ).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.